There are 2789 resources available
1474P - Patient characteristics and treatment patterns in patients with metastatic pancreatic cancer by BRCA/ATM status in the PRIOR-2 study
Presenter: Maria Sierra
Session: ePoster Display
1475P - Results of a randomized, double-blind, placebo-controlled, phase II study of gemcitabine and nab-paclitaxel ± olaratumab in treatment-naïve patients with unresectable metastatic pancreatic cancer
Presenter: Faithlore Gardner
Session: ePoster Display
1478P - Trends in treatment patterns among Medicare fee-for-service (FFS) patients receiving treatment for metastatic pancreatic cancer
Presenter: Gabriela Dieguez
Session: ePoster Display
1479P - Exploring second-line therapy outcome in pancreatic ductal adenocarcinoma (PDAC) patients with germlineBRCA1-2 pathogenic variants (gBRCA1-2pv)
Presenter: Giulia Orsi
Session: ePoster Display
1480P - Real-world progression outcomes among patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan-based regimens in the United States
Presenter: George Kim
Session: ePoster Display
1481P - Predictors for 30-day readmission in patients with pancreatic cancer who had DNR code status
Presenter: Jasmeet Kaur
Session: ePoster Display
1482P - Landscape of germline pathogenic variants beyond BRCA in pancreatic cancer patients
Presenter: Roberto Borea
Session: ePoster Display
1483P - Cell-free DNA dominant clone allele frequency associates with poor outcomes in advanced pancreatic cancer
Presenter: Pedro Uson Junior
Session: ePoster Display